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1. Introduction 
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) 
characterized by the reciprocal translocation t(15;17)(q22;q12) resulting in the fusion gene 
PML-RARA and an oncoprotein that impairs myeloid differentiation (Arber et al., 2008; de 
The et al., 1990; Rowley et al., 1977). Morphological and clinical characteristics include 
hypergranular leukemic promyelocytes, Auer rods, and coagulopathy. The use of all-trans 
retinoic acid (ATRA) has revolutionized the management of this disease that has become the 
most curable form of AML in adults (Castaigne et al., 1990; Tallman et al., 1997). In relapsed 
APL, arsenic trioxide can induce complete morphological, cytogenetic and molecular 
remission (Douer and Tallman, 2005; Soignet et al., 1998).  
Cases lacking the classic t(15;17) are divided into two separate groups that behave 
differently and are now considered different disease entities (Arber et al., 2008). The first 
group represents cryptic and complex APL where t(15;17) is absent on routine cytogenetic 
studies but PML-RARA is present on molecular studies (Grimwade et al., 2000). This group 
shares the same phenotype, prognosis, and sensitivity to ATRA as classic APL, and is thus 
managed similarly. The second group, “AML with a variant RARA translocation”, is no 
longer considered part of APL and includes acute myeloid leukemias with translocations 
involving RARA and a variety of partner genes other than PML (Arber et al., 2008). 
Compared to classic APL, these leukemias often exhibit significant differences in malignant 
phenotype and sensitivity to ATRA which will be further explored in this chapter.  
2. Clinical characteristics 
APL represents less than 10% of all AML, but seems to be over-represented in Hispanics 
(Yamamoto and Goodman, 2008). The median age of presentation is approximately 40 years 
(Vickers et al., 2000). Leukocytosis is only seen in about 25% of patients, and organomegaly 
is rarely found on diagnosis. The most common presenting signs are pancytopenia, fever, 
anemia, and bleeding. The latter can be fatal especially if occurring in the central nervous 
system (CNS), and is due to the combination of thrombocytopenia and the dreaded 
coagulopathy of APL (Warrell et al., 1993).  
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Abnormal promyelocytes are larger than their normal counterparts, with a nucleus that is 
often bilobed or kidney-shaped. 75% of APL cases are hypergranular (M3) with densely-
packed cytoplasmic granules that are bright pink, red, or purple, in addition to Auer rods in 
bundles called “faggot cells”. The remaining 25% of cases are microgranular or 
hypogranular (M3v), the granules being visualized by electron microscopy but not light 
microscopy, and the cytoplasm may contain a few fine azurophilic granules.  
In APL, myeloperoxidase (MPO) is strongly positive in all leukemic promyelocytes, and this 
can be especially helpful in microgranular APL which is sometimes confused with acute 
monocytic leukemia (Arber et al., 2008).  
4. Immunophenotype 
APL cells are usually CD13 positive and especially CD33 positive, but are characterized by 
low or absent expression of HLA-DR, CD34, CD11a, CD11b, CD18, and CD117 (Paietta et 
al., 2004). Hypogranular APL frequently coexpresses CD34 and CD2 (Exner et al., 2000). 
Expression of CD56 has been observed in about 20% of cases and confers a worse outcome 
(Ferrara et al., 2000). 
5. Pathogenesis 
APL is caused by the reciprocal translocation t(15;17)(q22;q12) that results in the fusion gene 
PML-RARA and an oncoprotein that impairs myeloid differentiation (Grignani et al., 1993). 
PML and RARA are both involved in normal hematopoiesis, and disruption of their 
physiologic roles by the formation of PML-RARA is essential to leukemogenesis. 
PML possesses physiologic growth suppressor and proapoptotic properties that are 
disrupted by PML-RARA, possibly by the abnormal positioning of PML away from the 
nuclear body structure, thus contributing to leukemic transformation (Wang et al., 1998). 
Following this logic, treatment with ATRA restores the normal localization of PML, 
allowing the resumption of its physiologic functions. 
On the other hand, RARA normally binds to response elements at the promoter region of 
target genes through heterodimerization with the retinoid X receptor (RXR). RARA-RXR 
results in the recruitment of nuclear corepressors (N-CoR) and histone deacetylase (HDAC) 
that repress transcription and inhibit differentiation (Grignani et al., 1993). This is thought to 
take place through epigenomic changes including histone deacetylation or methylation 
(Licht, 2009) and could have therapeutic implications in the future, especially as to the 
efficacy  of histone deacetylase inhibitor in APL refractory to conventional treatment with 
ATRA. Physiologic amounts of retinoid acid (RA) unbind the N-CoR from RAR-RXR, 
allowing for activation of transcription of RARA target genes and myeloid differentiation. In 
the presence of PML-RARA, normal concentrations of RA are not enough for that separation 
and pharmacologic doses of ATRA are needed to allow myeloid differentiation (Warrell et 
al., 1993). Arsenic trioxide (ATO) can also lead to differentiation, but it does so by inducing 
degradation of the PML-RARA fusion transcript. Both drugs have recently been shown to 
also work on an entirely different level in APL by eradicating “leukemia-initiating cells” or 
“leukemic stem cells” (Nasr et al., 2009), leading to think that their combination in induction 
regimens could result in higher rates of prolonged remissions and cure. 
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6.1 Classic t(15;17) APL 
Around 92% of APL patients have the balanced t(15;17), leading to the fusion of the retinoic 
acid receptor-alpha (RARA) gene on chromosome 17 and the promyelocytic leukemia (PML) 
gene on chromosome 15 (Grimwade et al., 2000) (Fig. 1). FISH uses a dual color dual fusion 
probe to detect PML-RARA rearrangements. The typical normal FISH pattern for the dual 
color, dual fusion probe is 2 red signals (2R) and 2 green signals (2G) for the PML and RARA 
loci respectively. When t(15;17) is present, the  characteristic FISH pattern is one red, one 
green and two fusion signals (Fig. 2). 
Whereas the breakpoints in RARA are invariably at intron 2, those in PML can occur at any 
one of three breakpoint cluster regions (Bcr): intron 6 (Bcr1), exon 6 (Bcr2), and intron 3 
(Bcr3) (Pandolfi et al., 1992). The 3 respective ensuing mRNA types, long (L)-form, variable 
(V)-form, and short (S)-form, can exhibit different phenotypes but do not affect complete 
remission (CR) rate or disease-free survival (DFS). The S-form, for example, is associated 
with increased leukocytosis which by itself is an adverse risk factor in APL, but after 
adjusting for that, does not independently influence CR rate and OS (Gallagher et al., 1997). 
The V form, originally thought to be less sensitive to ATRA, was later shown to be as 
equally sensitive to it as the other two types (Slack et al., 2000).  
6.2 Cryptic and complex APL  
As mentioned before, t(15;17) is absent in around 8% of patients diagnosed with APL 
(Grimwade et al., 2000), which should lead to the adoption of PML-RARA as the hallmark of 
APL. Cases lacking t(15;17) are divided into two separate disease entities: on one hand, 
cryptic and complex APL that share the same phenotype, prognosis, and sensitivity to 
ATRA as classic APL; and on the other hand, AML with a variant RARA translocation 
(Arber et al., 2008) which will be discussed later in this chapter. 
In cryptic and complex APL, the classic t(15;17) is absent on routine cytogenetic studies but 
PML-RARA is present on molecular studies; the leukemia is morphologically and clinically 
similar to t(15;17) positive APL and is treated as such. The European working party was 
crucial in characterizing the rare APL cases lacking the classic t(15;17) on routine cytogenetic 
studies. 4% of the cases represented cryptic/masked APL with submicroscopic insertion of 
RARA into PML leading to the expression of the PML-RARA transcript, while 2% had 
complex variant translocations involving chromosomes 15, 17 and an additional 
chromosome, and were sub-classified as: (a) complex variant t(15;17) due to a 3-way 
balanced translocation involving 15q22, 17q21, and another chromosome; (b) simple variant 
t(15;17) involving 15q22 or 17q21 with another chromosome; and (c) very complex cases 
(Grimwade et al., 2000). 
In these unusual cases, the diagnosis can be missed by conventional cytogenetic studies, and 
molecular methods are needed such as fluorescence in situ hybridization (FISH) (Fig. 2), 
reverse transcriptase polymerase chain reaction (RT-PCR) and direct sequencing. FISH is often 
not sensitive enough to detect small cryptic insertions (Han et al., 2007; Kim et al., 2008; Wang 
et al., 2009), while RT-PCR can also face technical challenges such as atypical PML-RARA 
rearrangement with new breakpoints in the PML gene that cannot be amplified with 
conventional primers (Barragan et al., 2002; Park et al., 2009), insertions of the PML gene to the 
RARA but too far apart to permit elongation and amplification of the PML-RARA sequence 
(Tchinda et al., 2004), or submicroscopic deletions of the 3’ RARA (Han et al., 2009).  
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Fig. 1. G-banded karyotype with t(15;17)(q22;q21) at arrows. 
 
 
Fig. 2. Dual color dual fusion break apart probe for detection of PML-RARA rearrangement. 
Panel A shows a normal FISH pattern (2R,2G), whereas panel B reveals fusion of the PML 
and RARA loci at arrows. 
6.3 AML with a variant RARA translocation  
This term is now used by the WHO (World Health Organization) to designate a subset of 
acute myeloid leukemias morphologically similar to APL, but lacking both t(15;17) by 
cytogenetics and PML-RARA by FISH and RT-PCR (Arber et al., 2008). They do, however, 
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show different variant translocations involving RARA and 1 of 7 partner genes: ZBTB16 
(previously known as promyelocytic leukemia zinc finger gene or PLZF) on chromosome 
11q23 (Licht et al., 1995), NUMA1 (nuclear matrix-mitotic apparatus protein 1 gene) on 
chromosome 11q13 (Wells et al., 1996), NPM1 (nucleophosmin gene) on chromosome 5q35 
(Corey et al., 1994; Hummel et al., 1999), STAT5B (signal transducer and activator of 
transcription 5 beta) on chromosome 17q21.1-21.2 (Zelent et al., 2001), PRKAR1A (protein 
kinase, cAMP-dependent, regulatory, type I, alpha) on chromosome 17q24 (Catalano et al., 
2007), FIP1L1 (factor interacting with PAP 1-like 1) on chromosome 4q12 (Buijs and Bruin, 
2007), and BCOR (BCL6 corepressor gene) on chromosome X (Yamamoto et al., 2010). Of the 
partner genes, the first 4 were included in the latest WHO classification, while the last 3 
have been described since. As with other hematological malignancies, partner genes affect 
both neoplastic phenotype and response to treatment including ATRA, making their 
identification crucial in the evaluation of these patients. 
6.3.1 ZBTB16-RARA 
The ZBTB16 or PLZF gene encodes for a zinc finger transcription factor of 673 amino acids 
(Chen et al., 1993). Its expression may play a role in the life of hematopoietic stem cells and 
seems to be down-regulated with differentiation (Shaknovich et al., 1998). Like PML, it 
possesses tumor suppressor activity that seems to be disturbed by t(11;17)(q23;q21) (Zelent 
et al., 2001). The European working party on APL found the t(11;17)(q23;q21) translocation 
in 0.8% of APL patients (Grimwade et al., 2000). The first case was identified in a Chinese 
patient from Shanghai (Chen et al., 1993), and more than 16 cases have been described since. 
The clinical presentation is usually indistinguishable from APL, with a low peripheral WBC 
count and a preponderance of promyelocytes in the bone marrow. The leukemic cells are 
usually microgranular, have a regular nucleus instead of bilobed, no Faggot cells, and there 
is often an increased number of Pelger-Huet-like cells (Sainty et al., 2000). The blasts are 
typically HLA-DR and CD34 negative, CD13 and CD33 positive. Several cases were strongly 
positive for the CD56 NK cell antigen.  
The tumor suppressor properties of ZBTB16 are thought to be inhibited by the ZBTB16-
RARA fusion protein in t(11;17)(q23;q21). Except for anecdotal reports, patients with 
ZBTB16-RARA are resistant to ATRA since pharmacological doses of the drug fail to 
dissociate ZBTB16 from the co-repressors (Licht et al., 1995).  
6.3.2 NUMA1-RARA 
The nuclear matrix-mitotic apparatus protein 1 gene (NUMA1) on chromosome 11q13 is a 
236 kDa protein that serves in the completion of mitosis, is thought to be involved in the 
regulation of transcription and is affected by post-translational changes (Harborth et al., 
2000; Saredi et al., 1996). So far, there’s only been a single report of a patient with NUMA1-
RARA, a 6 month-old boy who was diagnosed with APL with atypical features, received 
ATRA and was in complete remission (CR) more than 24 months following a bone marrow 
transplant (Wells et al., 1997; Wells et al., 1996). The pathogenesis of this leukemia is not 
well understood, but is thought to share several features with PML-RARA APL.  
6.3.3 NPM1-RARA 
The nucleophosmin gene (NPM1) plays a role in several important cell functions from the 
transportation of ribosomal precursors between cytoplasm and nucleolus (Szebeni et al., 
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1997), to cell growth control (Zelent et al., 2001) and activation of transcription (Shi et al., 
1997). It had been implicated in hematological malignancies including anaplastic lymphoma 
(Morris et al., 1994) and myelodysplastic syndrome (Yoneda-Kato et al., 1996). The NPM1-
RARA fusion is a rare variant translocation (less than 0.5%) and has so far been reported in 
pediatric patients, with absent Auer rods but otherwise variable morphology. In contrast to 
classic APL, CD13 is negative, but the rest of the immunophenotype is similar to classic APL 
including absence of CD56. The reported cases have been very sensitive to treatment with 
ATRA (Corey et al., 1994; Grimwade et al., 2000; Hummel et al., 1999; Redner et al., 1996).  
6.3.4 STAT5B-RARA 
STAT5B is one of many latent cytosolic transcription factors to be activated by janus kinase 
(JAK) tyrosine kinases, allowing it to move to the nucleus where it regulates gene 
transcription (Arnould et al., 1999). To date, only 4 cases of AML with STAT5B-RARA have 
been reported, all men in their fourth to sixth decade of life, with a predilection for 
disseminated intravascular coagulation (DIC) but otherwise heterogeneous clinical, 
morphologic and immunophenotypic characteristics. Finally, STAT5B-RARA is resistant to 
ATRA, similarly to ZBTB16-RARA. (Arnould et al., 1999; Iwanaga et al., 2009; Kusakabe et 
al., 2008).  
6.3.5 PRKAR1A-RARA 
PRKAR1A refers to protein kinase, cAMP-dependent, regulatory, type I, alpha. 
Protein kinase A (PKA) is a multimeric protein which activity is dependent on cyclic 
adenosine monophosphate (cAMP). Downregulation of PKA occurs when 
phosphodiesterase, one of the substrates activated by the kinase, converts cAMP to AMP, 
effectively decreasing cAMP that can activate PKA. There’s only one reported case of AML 
with PRKAR1A-RARA in a 66 year-old man. He presented with a normal WBC count, had a 
hypercellular marrow with 88% hypergranular promyelocytes, regular nuclei, and absent 
Auer rods and faggot cells. MPO was strongly positive, but expression of CD13, CD33, and 
CD11b was weak. The cells were negative for CD2, CD19, CD34, CD56, CD117, and HLA-
DR (Catalano et al., 2007).  
6.3.6 FIP1L1-RARA 
Human FIP1 is an integral subunit of cleavage and polyadenylation specificity factor (CPSF), 
and plays a significant role in poly(A) site recognition and cooperative recruitment of poly(A) 
polymerase to the RNA (Kaufmann et al., 2004). Only 2 cases of FIP1L1-RARA have been 
described, and the entity seems to be sensitive to ATRA. The first case involved a 90 year-old 
woman who was clinically diagnosed with APL and achieved a complete remission by oral 
administration of ATRA alone. No further details were described in the paper as to clinical 
presentation, morphology, or immunophenotypic analysis (Kondo et al., 2008). 
The second case involved a 20 month-old boy who was diagnosed with juvenile 
myelomonocytic leukemia after presenting with leukocytosis and anemia. Bone marrow 
aspirate showed hypercellularity including 11% promyelocytes, 25% myelocytes, 12% 
metamyelocytes, and 8% myelomonoblasts. These cells were hypergranular but had regular 
nuclei and no Auer rods. Immunophenotypic analysis was not published. Unfortunately, 
the patient did not receive ATRA, had an allogeneic stem cell transplant but died from 
relapse a few months later. 
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As its name implies, BCOR is a corepressor of transcription through the oncoprotein BCL6, 
and its activity could be disrupted by the formation of BCOR-RARA (Huynh et al., 2000). 
There’s only one such case reported in the literature of a 45 year-old male patient who 
presented with leukocytosis and coagulopathy. Leukemic cells were MPO positive and less 
granular than classic APL. Interestingly, the cytoplasm contained periodic acid–Schiff 
rectangular and round cytoplasmic inclusion bodies and lacked Auer bodies and faggot 
cells. Immunophenotypic analysis showed HLA-DR negativity but positivity for CD33, 
CD13 and CD56. The patient was clinically responsive to ATRA but had several relapses 
with chemotherapy and ATRA (Yamamoto et al., 2010).  
7. Treatment 
In the previous section, we depicted the reported cases of AML with a variant RARA 
translocation, their response to treatment, and their varying sensitivity to ATRA depending 
on the partner gene. We will now discuss the management of classic APL, and cryptic and 
complex APL; these all share the same phenotype, prognosis, and sensitivity to ATRA, and 
therefore are treated similarly.  
7.1 Induction therapy 
When left untreated, APL is the deadliest form of AML with a median survival of less than 
30 days (Hillestad, 1957). The introduction of ATRA in 1980 (Breitman et al., 1980) 
completely revolutionized the management of this disease that now boosts complete 
remission rates of 80 to 95% and cure rates of around 80% (Sanz and Lo-Coco, 2011). ATRA 
sets off the differentiation of malignant promyelocytes into mature granulocytes, improves 
homeostasis and shortens the duration of the dreaded coagulation syndrome of APL. It also 
generates the eradication of “leukemia-initiating cells” or “leukemic stem cells”, a property 
shared by arsenic trioxide (ATO). In mice, a combination of both drugs can actually result in 
the elimination of leukemia-initiating cells and effectively “cure” APL (Nasr et al., 2009), 
opening the door to future trials combining ATRA and ATO without the use of 
chemotherapy. As mentioned before, if APL is suspected clinically and cytologically, ATRA 
should be promptly started even if cytogenetic and molecular confirmations of the diagnosis 
are pending.  
Because of the short duration of CR with ATRA alone, and the known sensitivity of APL to 
anthracyclines (Head et al., 1995), the current standard induction regimen in APL is the 
administration of ATRA with anthracycline-based chemotherapy. This combined approach 
has been shown to be superior to a previously adopted sequential treatment of ATRA 
followed by chemotherapy (Fenaux et al., 1999). The median time to CR ranges from 38 to 44 
days but could be as long as 90 days. In addition to its effect on CR, chemotherapy controls 
leukocytosis that is common when ATRA is used alone. In patients who have 
contraindications to anthracycline chemotherapy, the combination of ATRA and arsenic 
trioxide (ATO) for induction treatment should be considered (Sanz et al., 2009). The current 
standard chemotherapy regimens use daunorubicin with cytarabine or idarubicin alone, 
while there’s a lack of experience and data with other anthracyclines. These 2 regimens have 
indirectly yielded comparable CR rates (Fenaux et al., 1999; Mandelli et al., 1997). When 
daunorubicin was used without cytarabine in one randomized prospective trial of young 
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patients with APL, the CR rates were similar but there were more relapses and lower overall 
survival in patients who did not get cytarabine (Ades et al., 2006). The additional benefit 
conferred by cytarabine, however, did not apply to all patients and was only observed in 
those with WBC > 10x109/L (Ades et al., 2008) who are high-risk patients by Sanz’s risk 
stratification (Table 1) (Sanz et al., 2000; Sanz et al., 2004). Based on these results and the 
findings of other trials suggesting a similar role for cytarabine in consolidation (Sanz and 
Lo-Coco, 2011), we recommend that APL patients younger than 60 years old with WBC > 
10x109/L receive cytarabine in addition to ATRA and an anthracycline. Other indicators of 
relapse, such as CD56 positivity, do not currently alter treatment decisions (Ferrara et al., 
2000).  
7.2 Consolidation therapy  
Five to six weeks following induction, patients should be re-evaluated with bone marrow 
aspirate/biopsy and cytogenetics, while RTC-PCR for PML-RARA is not required since the 
transcript will still be detectable in about half of patients. Those in remission (> 90% of 
patients) will proceed with consolidation treatment to prevent relapse. This involves the use 
of an anthracycline (± cytarabine in high-risk patients), in addition to ATRA (Sanz et al., 
2004; Sanz et al., 2008), but different regimens are still being prospectively studied.  
7.3 Maintenance therapy 
Molecular remission is required at the end of consolidation treatment, after which 
maintenance ATRA will increase disease-free survival and improve the 10-year cumulative 
incidence of relapse (Ades et al., 2010; Tallman et al., 2002). The most commonly used 
maintenance regimen lasts for 1 year and encompasses ATRA 45 mg/m2 orally daily for 15 
days every 3 months or 7 days every 2 weeks, 6-mercaptopurine 60 mg/m2 orally every 
evening, and methotrexate 20 mg/m2 orally every 7 days (Avvisati G, 2003). Patients 
require close surveillance for toxicities, myelosuppression, and abnormal liver function 
tests, in addition to RTC-PCR every 3 months to monitor for disease relapse. 
 
Risk stratification  3-year DFS 
Low risk WBC ≤ 10x109/L, PLT > 40x109/L  97% 
Intermediate risk WBC ≤ 10x109/L, PLT ≤ 40x109/L  97% 
High risk WBC > 10x109/L  77% 
Table 1. Risk stratification of APL patients based on WBC and Platelet (PLT) counts, and 
corresponding 3-year disease-free survival (DFS) following induction and consolidation 
therapies with ATRA + anthracycline-based chemotherapy, followed by standard 
maintenance (Sanz et al., 2000; Sanz et al., 2004)  
8. Refractory and relapsed disease 
8.1 Arsenic trioxide 
Patients who do not achieve cytogenetic remission after induction therapy and/or 
molecular remission after consolidation are considered to have refractory disease, while 
those in remission who suddenly have detectable PML-RARA by RTC-PCR have relapsed 
APL. In both situations, salvage treatment is needed and arsenic trioxide (ATO) can induce 
CR in 85 to 88% of patients, and this can be followed by stem cell transplantation (Soignet et 
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al., 2001; Soignet et al., 1998). ATO not only induces degradation of the PML-RARA fusion 
transcript, leading to differentiation of malignant promyelocytes, but also leads to the death 
of “leukemia-initiating cells” (Nasr et al., 2009).  
So far reserved for the treatment of refractory or relapsed disease, in addition to some use in 
patients with contraindications to anthracyclines (Sanz et al., 2009), ATO has and is 
currently being studied for use in first-line induction therapy alone or in combination with 
ATRA without any chemotherapy (Hu et al., 2009; Mathews et al., 2006). This, however, has 
not yet become standard of care.  
ATO is usually given at 0.15 mg/kg/day intravenously until hematologic remission or for a 
maximum of 60 days. The major side-effects of this drug are fluid retention, differentiation 
syndrome and QT prolongation (Unnikrishnan et al., 2004).  
8.2 Other agents 
Repeat treatment with ATRA and chemotherapy in refractory and relapsed APL has had 
disparate success, and other agents that might be of benefit in this setting are still under 
investigation including gemtuzumab, Hum195 which is an anti-CD33 antibody, sodium 
phenylbutyrate, and calcitriol. 
Of special note, tamibarotene, a synthetic retinoid synthesized by the University of Tokyo in 
1984 and 10 times more potent than ATRA, seems to be especially promising. Tamibarotene 
is approved in Japan for use in relapsed and refractory acute APL, and was successfully 
used at our institution (University of Texas Southwestern Medical Center) in a patient with 
relapsed and refractory extra-medullary APL (Naina et al., 2011). Tamibarotene is currently 
being compared to ATRA for maintenance therapy in the ongoing APL204, a randomized 
phase III trial of the Japan Adult Leukemia Study Group.  
9. Other considerations 
9.1 Coagulopathy 
Within the first 10 days of treatment, 5-10% of APL patients will develop fatal hemorrhage, 
especially in the central nervous system (CNS) and lungs (Rodeghiero et al., 1990). This is 
secondary to a characteristic coagulation disorder combining disseminated intravascular 
coagulation (DIC) and fibrinolysis that is not well understood. Platelets and cryoprecipitate 
should be transfused to maintain platelet counts more than 30-50x109/L, and fibrinogen 
level more than 150 mg/dL, respectively (Tallman et al., 2005). ATO and ATRA have both 
been shown to quickly correct this coagulation disorder, and the initiation of the latter has 
become a true emergency in any new APL patient. ATRA should be promptly started when 
APL is clinically and cytologically suspected even if cytogenetic and molecular 
confirmations of the diagnosis are pending (Sanz et al., 2009).  
9.2 Central Nervous System (CNS) prophylaxis 
The CNS is the most common site of extramedullary disease and relapse in APL (Evans and 
Grimwade, 1999), with elevated WBC count > 10x109/L being the only significant risk factor 
in a multivariate analysis (de Botton et al., 2006). There are no guidelines as to the systematic 
CNS prophylaxis of APL patients with leukocytosis. Groups who include intrathecal 
chemotherapy in their regimens administer it during consolidation, not during induction 
when the risk of fatal bleeding is high. ATO crosses the blood-brain barrier and is being 
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evaluated for use in first-line induction therapy; it is conceivable that such induction 
regimens will result in lower rates of CNS relapse.  
9.3 Differentiation syndrome 
Also known as the retinoic acid syndrome or cytokine storm, it is seen in around 25% of 
APL patients in the first 3 weeks following treatment with ATRA or arsenic trioxide (Vahdat 
et al., 1994). The differentiation syndrome is caused by the release of cytokines from 
neoplastic promyelocytes as they differentiate in response to treatment. Usual symptoms 
include fever, shortness of breath, peripheral edema, pulmonary infiltrates, hypoxemia, 
respiratory distress and hypotension. Patients can also develop renal and hepatic 
dysfunction, in addition to pleural and pericardial effusions. The syndrome can be fatal and 
prompt recognition is vital, leading to the initiation of intravenous dexamethasone 10 mg 
twice daily until clinical resolution, followed by slow steroid taper. Patients with WBC > 
10x109/L are suspected to be at increased risk, and some recommend treating this group 
prophylactically with steroids (Wiley and Firkin, 1995).  
10. Conclusion 
Over the last 2 decades, we have witnessed a change in acute promyelocytic leukemia from 
the most malignant form of AML to the most curable one; a remarkable medical 
achievement that did not rely on advances in chemotherapy, but rather on molecular 
targeted therapy in the form of differentiation agents. This innovative approach to the 
treatment of malignant neoplasms was later emulated by the use of tyrosine kinase 
inhibitors in chronic myeloid leukemia. The latest scientific breakthrough in APL is the 
discovery that ATRA and ATO not only induce differentiation but also eradicate “leukemia-
initiating cells” or “leukemic stem cells” (Nasr et al., 2009), leading to think that their 
combination in induction regimens could result in higher rates of prolonged remission and 
cure. This has opened the door to new clinical trials in APL and a rational that might prove 
one day applicable in other hematologic malignancies. 
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